Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

NeuroVive Pharmaceutical AB Interim Report January - September 2016

NeuroVive Pharmaceutical
Posted on: 22 Nov 16

Regulatory News:

NeuroVive (STO:NVP)

Business operations

Important events July-September 2016

  • NeuroVive completed a 10 percent partial acquisition of its business partner, Isomerase Therapeutics
  • NeuroVive received a request to terminate the Company’s license agreement with Arbutus Biopharma
  • NeuroVive’s strategy for the treatment of mitochondrial disease was published in Nature Communications

Important events after the end of the period

  • The development of CicloMulsion for acute kidney injury was discontinued and as a consequence the value of the subsidiary NeuroVive Asia has been written-down by 50 percent and all previously capitalized expenditure in connection with CicloMulsion has been recognized as an impaired value in the interim report for the third quarter
  • New business model encompassing out-licensing of projects for common indications, as well as proprietary development of orphan indication projects, was communicated
  • Positive preclinical results obtained in an experimental model for non-alcoholic steatohepatitis (NASH), a very serious and common disease for which no medication is currently available
  • In a termination agreement, all rights for NVP018 were returned to NeuroVive from Arbutus Biopharma. NeuroVive also received material manufactured by Arbutus valued at USD 1.5 million

Financial information

Third quarter (July – September 2016 )

  • Net revenues were SEK 0 (0) and other operating income was SEK 16,000 (74,000)
  • Loss before tax was SEK 34,290,000 (53,948,000), for further information see page 6
  • Loss per share* was SEK 0.86 (1.75)
  • Diluted loss per share** was SEK 0.86 (1.75)

First nine months of the year (January-September 2016 )

  • Net revenues were SEK 0 (2,502,000) and other operating income was SEK 90,000 (499,000)
  • Loss before tax was SEK 57,265,000 (83,435,000), for further information see page 6
  • Loss per share* was SEK 1.42 (2.78)
  • Diluted loss per share** was SEK 1.42 (2.78)

* Profit/loss for the period divided by the average number of shares before dilution at the end of the period.

**Profit/loss for the period divided by the average number of shares after dilution at the end of the period.

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20161121006309/en/

Business Wire
www.businesswire.com

Last updated on: 22/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.